Journal
DIABETOLOGIA
Volume 62, Issue 10, Pages 1835-1841Publisher
SPRINGER
DOI: 10.1007/s00125-019-4934-x
Keywords
Ageing; Cellular senescence; Dasatinib; Diabetes; Geroscience; Life course development; Quercetin; Review; Senolytics; Type 2 diabetes
Categories
Funding
- NIH [AG13925, AG041122, AG061456, AG31736, DK50456, AG46061]
- Connor Group
- American Federation for Aging Research (AFAR)
- Ted Nash Long Life Foundation
- Noaber Foundation
- Glenn/AFAR Scholarship for Research in the Biology of Aging
- Swedish Research Council
- Heart and Lung Foundation
- IngaBritt and Arne Lundberg Foundation
- Novo Nordisk Foundation
- Torsten Soderberg Foundation
- ALF agreement
- Swedish Diabetes Association
Ask authors/readers for more resources
Ageing and diabetes lead to similar organ dysfunction that is driven by parallel molecular mechanisms, one of which is cellular senescence. The abundance of senescent cells in various tissues increases with age, obesity and diabetes. Senescent cells have been directly implicated in the generation of insulin resistance. Recently, drugs that preferentially target senescent cells, known as senolytics, have been described and recently entered clinical trials. In this review, we explore the biological links between ageing and diabetes, specifically focusing on cellular senescence. We summarise the current data on cellular senescence in key target tissues associated with the development and clinical phenotypes of type 2 diabetes and discuss the therapeutic potential of targeting cellular senescence in diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available